文献速递神经核医学

FDG-PET在原发性进行性失语不同亚型鉴别诊断中的诊断效用

Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-05-09

欧洲核医学协会(EANM)与欧洲神经病学学会(EAN)联合工作组就FDG-PET在神经退行性疾病中的应用制定临床指导。本文针对FDG-PET在三种原发性进行性失语(PPA)亚型鉴别中相对于临床/神经心理评估的诊断效用,经文献检索与德尔菲共识,认为支持其临床效用的正式证据水平差,但七名专家中六名支持临床使用。

要点

  • 支持FDG-PET鉴别PPA亚型临床效用的正式证据水平被认为较差。
  • 德尔菲第一轮中七名专家有六名支持临床使用FDG-PET。
  • 专家支持依据为PPA诊断标准需典型萎缩或代谢模式,且FDG-PET所检突触功能障碍早于萎缩。

核心结论

  • 展示FDG-PET效用或缺乏效用的定量证据仍缺失。
  • 专家一致决定基于PPA诊断标准需典型萎缩或代谢模式、且FDG-PET检测的突触功能障碍早于萎缩这一事实,提供临床使用的临时支持。
  • 正常FDG-PET指向非神经退行性病因。

研究设计与样本

  • 由EANM和EAN任命七名专家组成专家组,使用统一的PICO(人群、干预、比较、结局)问题关键词进行文献检索。
  • 对研究进行合格性筛选并提取数据以评估其方法学质量,关键结局为鉴别不同PPA临床形式的准确性指标。
  • 随后利用提取数据和质量评估进行德尔菲轮次,基于文献和专家意见达成共识。

主要发现

  • 所检查论文中有四篇可获得该PICO的关键结局。
  • 支持FDG-PET鉴别PPA变异型临床效用的正式证据水平被认为较差。
  • 共识建议在德尔菲第一轮确定,七名专家中六名支持临床使用。

临床怎么用

  • 专家基于德尔菲第一轮七名中六名支持,为FDG-PET在PPA鉴别中的临床使用提供临时支持。
  • 专家支持依据为PPA诊断标准需典型萎缩或代谢模式,且FDG-PET检测的突触功能障碍早于萎缩。
  • 正常FDG-PET指向非神经退行性病因。

局限性

  • 支持FDG-PET鉴别PPA变异型临床效用的正式证据水平被认为较差。
  • 展示FDG-PET效用或缺乏效用的定量证据仍缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A joint effort of the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) aims at clinical guidance for the use of FDG-PET in neurodegenerative diseases. This paper addresses the diagnostic utility of FDG-PET over clinical/neuropsychological assessment in the differentiation of the three forms of primary progressive aphasia (PPA). METHODS: Seven panelists were appointed by the EANM and EAN and a literature search was performed by using harmonized PICO (Population, Intervention, Comparison, Outcome) question keywords. The studies were screened for eligibility, and data extracted to assess their methodological quality. Critical outcomes were accuracy indices in differentiating different PPA clinical forms. Subsequently Delphi rounds were held with the extracted data and quality assessment to reach a consensus based on both literature and expert opinion. RESULTS: Critical outcomes for this PICO were available in four of the examined papers. The level of formal evidence supporting clinical utility of FDG-PET in differentiating among PPA variants was considered as poor. However, the consensual recommendation was defined on Delphi round I, with six out of seven panelists supporting clinical use. CONCLUSIONS: Quantitative evidence demonstrating utility or lack thereof is still missing. Panelists decided consistently to provide interim support for clinical use based on the fact that a typical atrophy or metabolic pattern is needed for PPA according to the diagnostic criteria, and the synaptic failure detected by FDG-PET is an earlier phenomenon than atrophy. Also, a normal FDG-PET points to a non-neurodegenerative cause.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bouwman F, Orini S, Gandolfo F, et al. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur J Nucl Med Mol Imaging. 2018. PMID: 29744573. doi:10.1007/s00259-018-4034-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。